within Pharmacolibrary.Drugs.ATC.B;

model B01AE07
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.066,
    Cl             = 0.00017833333333333332,
    adminDuration  = 600,
    adminMass      = 150 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.026833333333333334,
    Tlag           = 19.2,            
    Vdp             = 0.09,
    k12             = 20.7,
    k21             = 20.7
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>B01AE07</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Dabigatran etexilate is an oral direct thrombin inhibitor used for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, and for treatment and prevention of deep vein thrombosis and pulmonary embolism. It is approved and widely used today as a novel oral anticoagulant (NOAC).</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers, both male and female, following a single oral dose.</p><h4>References</h4><ol><li><p>Hindley, B, et al., &amp; Penson, PE (2023). Pharmacokinetics and pharmacodynamics of direct oral anticoagulants. <i>Expert opinion on drug metabolism &amp; toxicology</i> 19(12) 911–923. DOI:<a href=\"https://doi.org/10.1080/17425255.2023.2287472\">10.1080/17425255.2023.2287472</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37991392/\">https://pubmed.ncbi.nlm.nih.gov/37991392</a></p></li><li><p>Stangier, J, &amp; Clemens, A (2009). Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. <i>Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis</i> 15 Suppl 1 9S–16S. DOI:<a href=\"https://doi.org/10.1177/1076029609343004\">10.1177/1076029609343004</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19696042/\">https://pubmed.ncbi.nlm.nih.gov/19696042</a></p></li><li><p>Elenjickal, EJ, et al., &amp; Mavrakanas, TA (2024). Anticoagulation in Patients with Chronic Kidney Disease. <i>American journal of nephrology</i> 55(2) 146–164. DOI:<a href=\"https://doi.org/10.1159/000535546\">10.1159/000535546</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38035566/\">https://pubmed.ncbi.nlm.nih.gov/38035566</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end B01AE07;
